A-HeFT

African-American Heart Failure Trial

Paciente / Población Intervención / Exposición Comparación Desenlace

In 1,050 Black patients with NYHA III-IV HFrEF on standard therapy, fixed-dose isosorbide dinitrate plus hydralazine improved a composite of survival, HF hospitalisation and quality of life compared with placebo.

1050

Diseño

Double-blind placebo-controlled RCT, stopped early for benefit

Desenlace

Weighted composite score (all-cause death, first HF hospitalisation, change in quality of life)

Relevancia

ResultadoComposite score significantly favoured active therapy; trial halted early for mortality benefit (6.2% vs 10.2% deaths; HR 0.57, P=0.01) and fewer first HF hospitalisations (16.4% vs 22.4%).

Taylor AL, et al. N Engl J Med. 2004;351(20):2049-2057. 10.1056/NEJMoa042934

Discusión y crítica

Enrolled only self-identified Black patients already on ACEi/beta-blockers, limiting generalisability and raising questions about race-based prescribing. Established fixed-dose isosorbide dinitrate/hydralazine as add-on therapy.